Afqlir 40 mg/ml oplossing voor injectie in een injectieflacon
As listed in the register: Afqlir 40 mg/ml oplossing voor injectie in een injectieflacon
40 mg/ml · oplossing voor injectie
- Prescription only
- Eyes and ears
- Active substance
- Aflibercept
- Used in
- Eyes and ears
- Made by
- Sandoz GmbH
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (EYLEA). It describes the substance, not this exact product.
Vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) are members of the VEGF family of angiogenic factors that can act as mitogenic, chemotactic, and vascular permeability factors for endothelial cells.
VEGF acts via two receptor tyrosine kinases, VEGFR-1 and VEGFR-2, present on the surface of endothelial cells.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-07-07
Safety of the active substance
From the US prescribing label for the same active substance (EYLEA). It describes the substance, not this exact product.
- Hypersensitivity reactions may manifest as rash, pruritus, urticaria, severe anaphylactic/anaphylactoid reactions, or severe intraocular inflammation.
The most common adverse reactions (≥5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
Spain16 matching products
- AFQLIR 40 mg/ml · solución inyectable en jeringa precargada2 makers
- EIYZEY 40 mg/ml · solución inyectable en jeringa precargada2 makers
- EYDENZELT 40 mg/ml · solución inyectable en jeringa precargada2 makers
- MYNZEPLI 40 mg/ml · solución inyectable en jeringa precargada2 makers
- OPUVIZ 40 mg/ml · solución inyectable en jeringa precargada2 makers
- PAVBLU 40 mg/ml · solución inyectable2 makers
- YESAFILI 40 mg/ml · solución inyectable en jeringa precargada2 makers
- AHZANTIVE 40 mg/ml · solución inyectable en jeringa precargada
France14 matching products
- EYDENZELT 40 mg · solution injectable2 makers
- EYLEA 40 mg · solution injectable2 makers
- MYNZEPLI 40 mg · solution injectable2 makers
- PAVBLU 40 mg · solution injectable2 makers
- YESAFILI 40 mg · solution injectable2 makers
- AFIVEG 40 mg · solution injectable
- AFQLIR 40 mg · solution injectable
- AHZANTIVE 40 mg · solution injectable
CanadaNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Sandoz GmbH |
|---|---|
| Active substance | Aflibercept |
| Used in | Eyes and ears |
| Strength | 40 mg/ml |
| Form | oplossing voor injectie |
| Classification | S01LA05 · Eyes and ears |
| Route | intravitreaal gebruik |
| Dispensing (as stated by the register) | Uitsluitend recept |
| RVG | EU/1/24/1867 |
Source: Geneesmiddeleninformatiebank · 2026-09-30 · not reviewed by a clinician
Bron: College ter Beoordeling van Geneesmiddelen (CBG). De Rijksoverheid is het niet automatisch eens met de inhoud van deze site. Reuse terms: CC0 1.0 (CBG website).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.